Placebo matching dostarlimab clinical trials

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.